Arnab Basu joins other technology bosses ‘frustrated’ with London’s small-cap market after Kromek’s share price dropped more than 90 per cent since 2013
Arnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.
Durham pupils' solar diamond lanterns introduced to Lumiere thenorthernecho.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenorthernecho.co.uk Daily Mail and Mail on Sunday newspapers.
Kromek Group PLC (AIM:KMK) said it has entered into a partnership with a blue-chip technology group to develop cadmium zinc telluride (CZT) based detectors.